Document and Entity Information [Abstract] Document and entity information. ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted Cash and Cash Equivalents, Current Short term restricted cash Restricted cash Due from Related Parties, Current Receivables from related party Receivables from related party Other current assets Other Assets, Current Assets, Current, Total Total current assets Property and equipment, net Property, Plant and Equipment, Net Other assets Other Assets, Noncurrent Assets, Total Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Deferred revenue Deferred Revenue, Related Party Current Deferred revenue, related party The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year including license fees, milestone payments and royalties, but excluding interest income. Other current liabilities Other Liabilities, Current Liabilities, Current, Total Total current liabilities Other long-term liabilities Other Liabilities, Noncurrent Deferred revenue, net of current portion Deferred Revenue, Noncurrent Deferred Revenue, Related Party Net of Current Portion Deferred revenue, related party, net of current portion The noncurrent portion of deferred revenue amount from related parties as of balance sheet date. Deferred revenue from related party is the carrying amount of consideration received or receivable as of the balance sheet date from a related party on potential earnings that were not recognized as revenue in conformity with GAAP and is not expected to be recognized in the next twelve months. Liabilities, Total Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Common Stock, Value, Issued Common stock, $0.001 par value; 200,000,000 shares authorized at September 30, 2012 and December 31, 2011; 133,882,699 and 107,218,463 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively Common shares, par value Common Stock, Par or Stated Value Per Share Common stock, par value Common stock, shares authorized Common Stock, Shares Authorized Common Stock, Shares, Issued Common stock, shares issued Common stock, shares outstanding Common Stock, Shares, Outstanding Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent, Total Total stockholders' equity Liabilities and Equity, Total Total liabilities and stockholders' equity Revenues: Revenues [Abstract] Collaboration Revenue Related Party Collaboration revenue - related party Revenue generated from a collaboration research, development and commercialization agreement with a related party which include payments to us for non-refundable license fees, milestones, collaborative research and development funding and royalties. Other Revenue, Net Other revenue Revenues, Total Total revenues Operating expenses: Costs and Expenses [Abstract] Cost of revenues Cost of Revenue Research and development Research and Development Expense General and administrative General and Administrative Expense Costs and Expenses, Total Total operating expenses Other Nonoperating Income (Expense) Other income, net Income Tax Expense (Benefit) Income tax expense Net income (loss) Net Income (Loss) Attributable to Parent Net income (loss) Earnings Per Share, Basic and Diluted Basic and diluted net loss per common share Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Share-based Compensation Total share-based compensation expense Share-based compensation expense Revenue Adjustment for Contingently Issuable Shares Revenue adjustment for contingently issuable shares The aggregate amount of noncash adjustment for revenue that is recorded related to a related party's stock subscription rights. Other Other Operating Activities, Cash Flow Statement Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Increase (Decrease) in Due from Related Parties, Current Receivables from related party Increase (Decrease) in Other Operating Assets Other assets Accounts payable Increase (Decrease) in Accounts Payable, Trade Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Other liabilities Increase (Decrease) in Other Operating Liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercise of common stock options Proceeds from Stock Options Exercised Proceeds from Issuance of Common Stock to Related Party Proceeds from issuance of common stock to related party The cash inflow from the additional capital contribution from a related party to the entity. Proceeds from Issuance of Common Stock Underwritten offering net proceeds Proceeds from issuance of common stock, net of offering costs Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Effect of changes in exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Change in Value of Shares of Common Stock Contingently Issuable or Issued to Related Party Change in value of shares of common stock contingently issuable or issued to related party The aggregate amount of noncash adjustment to additional paid-in capital that is recorded related to a related party's stock subscription rights. BUSINESS OVERVIEW Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Business Overview [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies [Abstract] Earnings Per Share [Text Block] NET INCOME (LOSS) PER COMMON SHARE Earnings (loss) per common share: Net Income (Loss) Per Common Share [Abstract] Collaborative Arrangement Related Party Disclosure [Text Block] NOVARTIS RELATIONSHIP Description of collaborative arrangement with a related party in which the entity is a participant, including a) information about the nature and purpose of such arrangement; b) its rights and obligations under there under; c) the accounting policy for collaborative arrangement with a related party and; d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between related party and the entity. Collaborative Arrangement Disclosure [Text Block] VIIV HEALTHCARE COMPANY AND GLAXOSMITHKLINE COLLABORATION INTANGIBLE ASSET, NET Intangible Assets Disclosure [Text Block] Intangible Asset, Net [Abstract] ACCRUED EXPENSES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] SHARE-BASED COMPENSATION Share-Based Compensation [Abstract] Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies [Abstract] Amendment Flag Current Fiscal Year End Date Document Period End Date Document Type Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Filer Category Entity Registrant Name Document Fiscal Period Focus Document Fiscal Year Focus Condensed Consolidated Balance Sheets [Abstract] Condensed Consolidated Statements of Cash Flows [Abstract] Business Overview (Textual) [Abstract] Business overview. Business Overview (Textual) [Abstract] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value Measurements Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-Based Compensation Cash and Cash Equivalents, Fair Value Disclosure Fair value of cash and cash equivalents Summary of Significant Accounting Policies (Textual) [Abstract] Summary of significant accounting policies. Summary of Significant Accounting Policies (Textual) [Abstract] Income (Loss) from Operations before Extraordinary Items, Per Basic Share [Abstract] Stock subscription rights and restricted stock awards Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Potential common shares excluded from calculation of diluted net loss per common share Stock Options [Member] Options [Member] Contingently Issuable Shares [Member] Contingently issuable shares to related party [Member] Effect of Dilutive Securities: Options, Shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potential common shares excluded from calculation of diluted net loss per common share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income (loss) Company One and Company Two Collaboration (Textual) [Abstract] ViiV Healthcare Company and Glaxosmithkline Collaboration (Textual) [Abstract] Company one and company two collaboration. Business Acquisition [Line Items] Amortization of Intangible Assets Amortization expense Intangible Asset, Net (Textual) [Abstract] Intangible Asset, Net. Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization Accrued Liabilities, Current [Abstract] Components of accrued expenses Other Accrued Liabilities, Current Other Settlement Liabilities, Current Short-term portion of accrued settlement payment Accrued Professional Fees, Current Professional fees Employee-related Liabilities, Current Payroll and benefits Research and Development Expense [Member] Research and development [Member] General and Administrative Expense [Member] General and administrative [Member] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Option activity under the equity incentive plans Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options outstanding at September 30, 2012, Number of Shares Options outstanding at December 31, 2011, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Stock options granted Granted, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Cancelled, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options exercisable at September 30, 2012, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options outstanding at September 30,2012, Weighted Average Exercise Price per Share Options outstanding at December 31,2011, Weighted Average Exercise Price per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Cancelled, Weighted Average Exercise Price per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options exercisable at September 30, 2012, Weighted Average Exercise Price per Share Gross Unrealized Gains Losses in fair Value Gross unrealized gains or losses in fair value Gross unrealized gains (losses) in fair value. Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Stock subscription rights and restricted stock awards Basic and Diluted Weighted Average Number of Common Shares Outstanding Basic and diluted weighted average number of common shares outstanding. Basic and diluted weighted average number of common shares outstanding Novartis [Member] Novartis [Member] Novartis. Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Legal Entity [Axis] Entity [Domain] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Axis] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Effective Date of Stock Purchase Agreement Effective date of GSK stock purchase agreement Effective date of stock purchase agreement. Viiv Healthcare Company and Glaxosmithkline Collaboration [Member] ViiV Healthcare Company and Glaxosmithkline Collaboration [Member] Viiv healthcare company and glaxosmithkline collaboration. Schedule of Related Party Transactions, by Related Party [Table] Related Party Transactions, by Related Party [Axis] Related Party [Domain] Life of Agreement License agreement, life Life of agreement. Aggregate Share-Based Compensation Expense to be Amortized Share-based compensation expense Aggregate share-based compensation expense to be amortized. Collaborative Arrangement Related Party Disclosure (Textual) [Abstract] Novartis Relationship (Textual) [Abstract] Collaborative arrangement related party disclosure. GSK [Member] GSK stock purchase agreement [Member] GSK. Earnings Per Share, Basic and Diluted [Abstract] Basic and diluted net loss per common share: Earnings Per Share, Diluted, Other Disclosures [Abstract] Potential common shares excluded from calculation of diluted net loss per common share Maturity Period of Cash and Cash Equivalents Maturity period of cash and cash equivalents Maturity period of highly liquid investments for classification of cash and cash equivalents. Aggregate Amount Contingently Payable to Stockholders by Related Party Aggregate amount contingently payable to stockholders by related party Aggregate amount contingently payable to stockholders by related party based on predetermined development milestones agreed upon in collaboration. Minimum Related Party Voting Stock Ownership for Director Election Minimum percentage of voting stock owned for director election Minimum percentage of voting stock owned by related party for nomination of election of director at least one designee of related party according to stockholders' agreement. Shares Issued Pursuant to Underwritten Offering Under Shelf Registration Statement Shares issued pursuant to underwritten offering under shelf registration statement filed with the SEC Shares issued pursuant to underwritten offering under shelf registration statement filed with the SEC. Shares Issued to Related Party Pursuant to Private Placement Agreement Shares issued to related party pursuant to a private placement agreement Shares issued to related party pursuant to private placement agreement. Fair Value of Common Stock Issued at Par Value to Related Party in Exchange of Termination of Stock Subscription Rights Fair Value of the common stock issued at par value to related party in exchange of termination of stock subscription rights Fair Value of the common stock issued at par value to related party in exchange for termination of stock subscription rights. Deferred Revenue Portion of Aggregate Impact of Related Party's Stock Subscription Rights Deferred revenue portion of aggregate impact of related party's stock subscription rights Deferred revenue portion of aggregate impact of related party's stock subscription rights under intrinsic model affecting non-refundable payments which are recorded as additional paid-in capital. License Fee Revenue Portion of Aggregate Impact of Related Party's Stock Subscription Rights License fee revenue portion of aggregate impact of related party's stock subscription rights License fee revenue portion of aggregate impact of related party's stock subscription rights under intrinsic model affecting non-refundable payments which are recorded as additional paid-in capital. Research and Development Accrued Expense Research and development contract costs Carrying value as of the balance sheet date of obligations incurred through that date related to research and development costs. Such amounts may include: (1) a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocate in accounting for a business combination to in-process projects deemed to have no alternative future use. Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Weighted average fair value of options Weighted Average Expected Term in Which Share Based Compensation Expense is Expected to be Amortized Weighted average expected term Weighted average expected term in which share based compensation expense is expected to be amortized. Cash Received from Purchase of Common Stock Outstanding by Related Party Cash received from purchase of capital stock outstanding by a related party at inception of collaboration Cash received from purchase of common stock outstanding by related party when collaboration agreement entered into. Purchase allowed related party to have the ability to exercise control over strategic direction, research and development activities and other material business decisions. Percentage of Issuance of Common Stock in Connection with Acquisition or in licensing of Technology in which Our Related Party has Right to Purchase at Par Value Such Number of Shares as is Required to Maintain its Percentage Ownership Percentage of issuance of common stock in connection with acquisition or in-licensing of technology in which our related party has the right to purchase, at par value, such number of shares as is required to maintain its percentage ownership Percentage of issuance of common stock in connection with acquisition or in-licensing of technology in which our related party has the right to purchase, at par value, such number of shares as is required to maintain its percentage ownership. Other Comprehensive Income (Loss), Net of Tax [Abstract] Changes in other comprehensive income: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Foreign currency translation adjustment Increase (Decrease) in Restricted Cash Increase in restricted cash License Agreement Terms [Member] ViiV license agreement [Member] Commitments and Contingencies (Textual) [Abstract] Commitments and Contingencies (Textual) [Abstract] Commitments and contingencies. Percentage of Net Sales Potentially Owed to Third Party Pursuant to Settlement Agreement Percentage of payments made towards settlement agreement on net sales Percentage of net sales potentially owed to a third - party pursuant to a settlement agreement. Minimum Sales Based Payment Potentially Owed to Third - Party Pursuant to Settlement Agreement Minimum sales-based payment pursuant to settlement agreement Minimum sales based payment potentially owed to a third - party pursuant to a settlement agreement. Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual [Axis] Title of Individual with Relationship to Entity [Domain] New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised, Weighted Average Exercise Price per Share Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted, Weighted Average Exercise Price per Share Schedule of Finite-Lived Intangible Assets [Table Text Block] Roll forward of intangible asset Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected option term (in years) Prior to amendment [Member] Prior to amendment. Officer [Member] Chief financial officer [Member] Schedule of Finite-Lived Intangible Assets [Table] Business Segments [Axis] Segment [Domain] Finite-Lived Intangible Assets [Line Items] University of Alabama at Birmingham Research Foundation [Member] UABRF [Member] University of Alabama at Birmingham Research Foundation. Intangible Asset, Net (Additional Textual) [Abstract] Intangible asset net. Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Option activity under the equity incentive plans Product Liability Contingency [Table] Product Liability Contingency [Line Items] Commitments and Contingencies (Additional Textual) [Abstract] Commitments and Contingencies (Additional Textual) [Abstract] Commitments and contingencies. License Agreement, Termination Date ViiV license agreement, terminated date License agreement termination date. Commitments and Contingencies Commitments and contingencies (Note 9) Trading Account Assets, Fair Value Disclosure Assets held at fair value Finite-lived Intangible Assets [Roll Forward] Rollforward of intangible asset Accrued Liabilities, Current Total accrued expenses Accrued expenses Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Share-based compensation expense in condensed consolidated statements of operations Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fair value per share and Black-Scholes option pricing model Share-based Compensation [Abstract] Share-based compensation expense in condensed consolidated statements of operations Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Fair value per share and Black-Scholes option pricing model Schedule of Accrued Liabilities [Table Text Block] Components of accrued expenses VIIV Healthcare Company and Glaxosmithkline Collaboration [Abstract] Increase Decrease Deferred Revenue Related Party Deferred revenue, related party The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received from a related party or recorded as a receivable. Deferred Revenue Recognized Period Deferred revenue recognized period. Deferred revenue recognized period Stock Issued During Period, Value, Other Aggregate purchase price of common stock under collaboration agreement Sale of Stock, Price Per Share Purchase price of common stock under collaboration agreement, per share Maturity Date of Settlement Agreement Related to Intangible Assets Maturity date of settlement agreement related to intangible assets Maturity date of settlement agreement related to intangible assets. Impact on License Fee Revenue as Result of Related Party's Stock Subscription Rights Impact on license fee revenue as a result of related party's stock subscription rights Impact on license fee revenue as a result of related party's stock subscription rights. Period for Related Party to Purchase Shares in Connection with Acquisition or in Licensing Period for related party to purchase shares in connection with acquisition or in-licensing. Period for related party to purchase shares in connection with acquisition or in-licensing Impact on Deferred Revenue as Result of Related Party's Stock Subscription Rights Impact on deferred revenue as a result of related party's stock subscription rights Impact on deferred revenue as a result of related party's stock subscription rights. Net Proceeds from Shares Issued Pursuant to Under written Offering Under Shelf Registration Statement and to Related Party Pursuant to Private Placement Agreement Net proceeds from shares issued pursuant to under written offering under shelf registration statement and to related party pursuant to private placement agreement Net proceeds from shares issued pursuant to underwritten offering under shelf registration statement filed with the SEC and shares issued to related party pursuant to private placement agreement. Minimum Percentage of Related Party Ownership for Consent Requirement of Selection and Appointment of CFO by Related Party Minimum percentage ownership of our common stock by related party for consent requirement of selection and appointment of CFO Minimum percentage ownership of our common stock by related party for consent requirement of selection and appointment of Chief Financial Officer by related party. Aggregate Impact of Related Party's Stock Subscription Rights Aggregate impact of related party's stock subscription rights Aggregate impact of related party's stock subscription rights under intrinsic model affecting non-refundable payments which are recorded as additional paid-in capital. Potential Milestone Payment Related to Settlement Agreement with Third Party Potential milestone payment related to a settlement agreement with a third-party Potential milestone payment related to a settlement agreement with a third-party. Liability Recorded as Result of Settlement Agreement with Third-Party Liability recorded as a result of a settlement agreement with a third-party Liability recorded as a result of a settlement agreement with a third-party. Royalty Revenue Related Party Revenue earned during the period from a collaboration research, development and commercialization agreement with a related party based on rights to certain property. Royalty revenue is derived from a percentage of net sales generated by the related party using the entity's property. Examples of property which royalties may be derived include patents. Royalty revenue - related party Deferred Revenue Related Party Revenue Recognized Deferred revenue, related party, recognized Amount of previously reported deferred or unearned revenue from a related party that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Potential Additional Milestone Payment Received Related to License Agreement Potential additional milestone payment received related to license agreement. Milestone payments did not meet our revenue recognition criteria for immediate recognition and are being recognized over the term of the agreement. Potential additional maximum milestone payments received related to ViiV license agreement Deferred Revenue, Current Impact On Additional Paid In Capital As Result Of Related Party Stock Subscription Rights Impact on additional paid-in capital as a result of related party's stock subscription rights. Impact on additional paid-in capital as a result of related party's stock subscription rights Stock Issued During Period, Shares, Other Common stock purchased under collaboration agreement Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities New Shelf Registration [Member] New shelf registration [Member] New shelf registration. Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] Subsidiary, Sale of Stock [Line Items] Third Party Settlement Third-party claim in inventorship rights Third party settlement. Common Stock Own Common stock owned Minimum interest rate issuance of capital shares Percentage of common stock outstanding owned by related party. Percentage of Outstanding Capital Stock from Stockholders Percentage of outstanding capital stock from stockholders Percentage of outstanding capital stock from stockholders. Negotiation Obligation Period for Parties Negotiation obligation period for parties Negotiation obligation period for parties in regards to any efforts to negotiate a future agreement between the related party and company. Earnings Per Share, Basic Basic EPS Basic Earnings Per Share, Diluted Diluted EPS Diluted Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Basic Basic EPS:Number of share outstanding Basic Weighted Average Number of Shares Outstanding, Diluted Diluted EPS:Number of share outstanding Diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Shares used in computing basic and diluted net loss per common share Schedule of Weighted Average Number of Shares [Table Text Block] Computation of basic and diluted earnings per share Computation Of Basic And Diluted Earnings Per Share Computation of basic and diluted earnings per share. Computation of basic and diluted earnings per share Earnings Per Share, Basic [Abstract] Basic EPS: Earnings Per Share, Diluted [Abstract] Diluted EPS: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Effect of Dilutive Securities: Novartis Non Exclusive License To Conduct Combination Trials [Member] Novartis Non-Exclusive License to Conduct Combination Trials [Member] Novartis? Non-Exclusive License to Conduct Combination Trials. Deferred Revenue Related Party Deferred revenue, related party The aggregate deferred revenue amount from a related party based on non-refundable payments made under the development and commercialization agreement. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Terms Of Related Party Termination Agreement Terms of a related party termination agreement Terms of the termination agreement with a related party in which deferred revenue, related party will be recognized as collaboration revenue- related party on a straight-line basis Deferred Revenue, Revenue Recognized Recognized deferred collaboration revenue Deferred revenue recognized as collaboration revenue Estimate Of Fair Value Of Related Party Stock Subscription Rights Estimate of the fair falue of related party's stock subscription rights Estimate of the fair value of related party's stock subscription rights. Shared Based Compensation (Textual) [Abstract] Shared based compensation. Shared Based Compensation (Textual) [Abstract] Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income (loss) before income taxes Operating Income (Loss) Income (loss) from operations Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive income (loss): Credit Facility [Axis] Credit Facility [Domain] Due from Related Parties, Noncurrent Receivables from related party, net of current portion Value Of Antidilutive Securities Included In Computation Of Dilutive Earnings Per Share Amount Effect of Dilutive Securities: Options, Value Value of securities issued to (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Value Of Antidilutive Securities To Related Party Included In Computation Of Dilutive Earnings Per Share Amount Effect of Dilutive Securities: Contingently issuable shares to related party, Value Value of securities issued to a related party (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Antidilutive Securities To Related Party Included In Computation Of Dilutive Earnings Per Share Amount Effect of Dilutive Securities: Contingently issuable shares to related party, Shares Securities issued to a related party (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Antidilutive Securities To Related Party Excluded From Computation Of Earnings Per Share Amount Contingently issuable shares to related party Securities issued to a related party (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Percentage Premium To Consideration Per Share Paid By Others For Related Party To Purchase Shares Percentage premium to the consideration per share paid by others for related party to purchase shares Percentage premium to the consideration per share paid by others to which related party has right to purchase to maintain its percentage ownership of our voting stock when shares are issued. Maximum Proceeds Allowed From Offer And Sale Of Common Stock Under Universal Shelf Registration Statement With Sec The maximum proceeds allowed from the offer and sale of common stock under a universal shelf registration statement with the SEC The maximum proceeds allowed from the offer and sale of common stock under a universal shelf registration statement with the SEC. Minimum Percentage Ownership Of Our Common Stock By Related Party To Have Option To License Our Development Stage Drug Candidates Minimum percentage ownership of our common stock by related party to have option to license our development stage drug candidates Minimum percentage ownership of our common stock by related party to have option to license our development stage drug candidates. Shares issued to related party in exchange for termination of stock subscription rights Shares issued to related party in exchange for termination of stock subscription rights Shares issued to related party in exchange for termination of stock subscription rights. Percentage Of Common Stock Outstanding Purchased By Related Party At Inception Of Collaboration Agreement Percentage of common stock outstanding purchased by a related party at inception of collaboration agreement Percentage of common stock outstanding purchased by a related party at inception of collaboration agreement. Percentage allowed related party to have the ability to exercise control over strategic direction, research and development activities and other material business decisions. Term In Years Through Which Royalties Are Payable To Related Party Term, in years, through which royalties are payable to a related party Term, in years, through which royalties are payable to a related party. This term begins after the first commercial sale of a product if royalties are payable on a product after the expiration of the patent rights in a specific country. Reduced Rate Of Royalty After Expiration Of Agreed Upon Term With Related Party Reduced rate of royalty after the expiration of agreed upon term with related party Reduced rate of royalty after the expiration of agreed upon term with related party. Percentage Of Payments To Thirdparty Based On Royalties Received From Related Party Percentage of payments to third-party based on royalties received from related party. Percentage of payments to third-party based on royalties received from related party Due from Related Parties Receivable and collaborative revenue-related party Minimum Percentage Of Voting Stock Owned By Related Party To Nominate For Election As Director At Least Two Related Party Designees Minimum percentage of voting stock owned by related party to nominate for election as director at least two related party designees Minimum percentage of voting stock owned by related party to nominate for election as director at least two designees of related party according to modification of collaboration agreement. Shares Of Common Stock Issued Pursuant To Underwritten Offering Shares of common stock issued pursuant to underwritten offering Shares of common stock issued pursuant to underwritten offering under shelf registration filed with the SEC. Minimum Percentage Of Voting Stock Owned By Related Party To Nominate For Election As Director At Least One Related Party Designee Minimum percentage of voting stock owned by related party to nominate for election as director at least one designee of related party according to modification of collaboration agreement. Minimum percentage of voting stock owned by related party to nominate for election as director at least one related party designee Achievement Of Preclinical Operational Milestone [Member] Achievement of preclinical operational milestone [Member] Achievement of a preclinical operational milestone. Initiation Of Phase I I B Clinical Study Of 761 [Member] Initiation of phase IIb clinical study of '761 [Member] Initiation of a phase IIb clinical study of ?761. Prior To Execution Of Termination Agreement [Member] Prior to execution of termination agreement. Prior to execution of termination agreement [Member] Collaboration Revenue Related To Non-Exclusive License [Member] Collaboration revenue related to the non-exclusive license [Member] Collaboration revenue related to the non-exclusive license. Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) [Abstract] Income available to common stockholders Novartis Reimbursement [Member] Novartis Reimbursement [Member] Novartis Reimbursement. Payment Obligations [Axis] Payment Obligations. Payment Obligations [Domain] Payment Obligations. Minimum Payment Obligations [Member] Minimum payment obligations [Member] Minimum payment obligations. Impairment of Intangible Assets (Excluding Goodwill) Intangible asset impairment Intangible asset impairment Novartis Relationship [Abstract] Restricted Cash and Cash Equivalents Restricted cash - Letter of credit issued Letters of Credit Outstanding, Amount Outstanding letter of credit Short term Restricted Cash [Member] Short term restricted cash [Member] Short term restricted cash. Long Term Restricted Cash [Member] Long term restricted cash. Long term restricted cash [Member] Asset impairment charges Restricted Cash and Cash Equivalents, Noncurrent Restricted cash Intangible Assets, Net (Excluding Goodwill) Ending balance Beginning balance Payment to UABRF as upfront payment for settlement agreement Intangible asset, net Deferred Revenue Milestone payment received related to ViiV license agreement Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised, Number of Shares Asset Impairment Charges Intangible asset impairment Breach Of Termination Agreement Maximum Days To Cure Breach of termination agreement, maximum days to cure Breach of termination agreement, maximum days to cure. Amount Of Shares Of Common Stock Which Were Issuable By Company Prior To Termination By Related Party Of Their Stock Subscription Right Amount of shares of common stock which were issuable by us prior to the termination by the related party of their stock subscription right Amount of shares of common stock which were issuable by us prior to the termination by the related party of their stock subscription right with respect to the exercise of stock options granted under a stock incentive plan. Minimum Number Of Related Party Designees To Be Nominated As Directors For At Least Thirty Percentage Of Voting Stock Minimum number of related party designees to be nominated as directors for at least 30% of voting stock Minimum number of related party designees to be nominated as directors for at least thirty percentage of voting stock. Minimum Number Of Related Party Designees To Be Nominated As Directors For At Least Nineteen Point Four Percentage Of Voting Stock Minimum number of related party designees to be nominated as directors for at least 19.4% of voting stock MinimumNumberOfRelatedPartyDesigneesToBeNominatedAsDirectorsForAtLeastThirtyPercentageOfVotingStock Net Amount Received Related To Collaboration Net amount received related to collaboration Net amount received related to collaboration.